Hair Testing for Ibutamoren Now Has a Detectable Dose Threshold

Anti-doping authorities have long struggled to contextualize hair test results in arbitration proceedings, partly because reference data linking known doses to measurable hair concentrations were largely absent for many newer performance-enhancing substances. Ibutamoren (MK-677), a potent oral growth hormone secretagogue increasingly used by athletes and biohackers to elevate IGF-1 and growth hormone levels, fell squarely into this interpretive gap.

To address this, forensic toxicologists administered a single 10 mg dose of ibutamoren to a male volunteer and collected hair four weeks later. Separately, hair was collected from a subject who had consumed an entire vial of 60 capsules at 10 mg each over roughly 90 days, also four weeks post-discontinuation. Samples were extracted using liquid/liquid extraction with bicalutamide-D4 as an internal standard and analyzed via validated chromatographic methods.

The results were striking. A single dose left a detectable signature of 1.3 pg/mg in the proximal hair segment (0–1 cm). Chronic use produced concentrations of 224 pg/mg across a 4 cm segment — nearly 170 times higher — marking the first confirmed demonstration of ibutamoren incorporation into human hair at doping-relevant doses.

These findings matter enormously for legal proceedings at the Court of Arbitration for Sport and in criminal forensic contexts. Previously, defense teams could argue that detected concentrations were uninterpretable without dose-response references. This study provides exactly that framework, allowing experts to differentiate incidental exposure from deliberate doping regimens.

Caveats include the very small sample size — essentially two individuals — and the fact that hair incorporation can vary by individual pigmentation, hair growth rate, and cosmetic treatments. Broader population studies are needed before universal thresholds can be firmly established.